Deltagen Announces Filing of Its 300th Application With the United States Patent and Trademark Office

Apr 10, 2001, 01:00 ET from Deltagen, Inc.

    MENLO PARK, Calif., April 10 /PRNewswire/ --
 Deltagen, Inc. (Nasdaq: DGEN), a genomic and biotechnology company, announced
 today the filing of its 300th application with the United States Patent and
 Trademark Office (USPTO), establishing Deltagen as a leader in the generation
 of genomic intellectual property for the biotechnology and pharmaceutical
 fields.
     The applications filed by Deltagen cover the functional utility of genes
 and additionally claim mammalian models useful for drug screening and
 discovery in a number of key disease areas, including cancer, immune system
 disorders, diabetes, inflammation, neuropsychological disorders, fertility and
 vision.  The applications also cover certain products and technologies,
 including Deltagen's proprietary methods relating to gene targeting, gene
 knockout and transgenic mouse production, and DeltaBase(TM), the company's
 database of gene function information.
     Adding approximately 63 new targets each quarter, DeltaBase currently
 contains 187 potential drug targets, predominantly representing classical drug
 discovery targets such as G-protein-coupled receptors, ion channels and
 proteases.  DeltaBase delivers 250 new gene targets annually, and Deltagen is
 pursuing patent protection on the functional utility of each of these targets.
     "The filing of our 300th application with the USPTO represents a
 significant milestone in Deltagen's rapidly-expanding intellectual property
 portfolio," said William Matthews, Ph. D., president and chief executive
 officer of Deltagen.  "Our USPTO filings, more than  275 in the past year
 alone, reflect Deltagen's continued commitment to drug discovery and
 commercialization efforts in the post-genome era," continued Dr. Matthews.
     Deltagen is a genomic and biotechnology company headquartered in
 Menlo Park, California, that provides data to pharmaceutical and biotechnology
 companies on the function, role and disease relevance of mammalian genes.
 This information may facilitate the discovery and validation of drug targets
 to advance the development of new genomics-based medicines.  Deltagen's
 principal product, DeltaBase(TM) provides a database of in vivo derived,
 mammalian gene function information.  In addition the Company offers a program
 dedicated to determining the function of secreted proteins.  Under this
 program, the Company undertakes the discovery and development of secreted
 protein biotechnology drug candidates internally or in collaboration with
 other parties.  Deltagen's current customers include GlaxoSmithKline plc,
 Merck Inc., Pfizer Inc. and Schering-Plough Research Institute.  The Company's
 current DeltaBase subscribers are GlaxoSmithKline plc and Pfizer Inc.
     NOTE:  This press release contains forward looking statements that are
 subject to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements, including
 uncertainties related to product and drug development, uncertainties related
 to the need for regulatory or other government approvals, the Company's
 patents and other intellectual property, dependence on proprietary technology,
 uncertainty of market acceptance of the company's products, uncertainties
 related to business opportunities, the receipt of future payments, including
 milestones and royalties, the continuation of customer relationships cited in
 the risk factors sections of the Company's Annual Report on Form 10-K filed
 with the Securities and Exchange Commission and the Company's other securities
 filings with the Commission.  These forward-looking statements speak only as
 of the date hereof.  The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 

SOURCE Deltagen, Inc.
    MENLO PARK, Calif., April 10 /PRNewswire/ --
 Deltagen, Inc. (Nasdaq: DGEN), a genomic and biotechnology company, announced
 today the filing of its 300th application with the United States Patent and
 Trademark Office (USPTO), establishing Deltagen as a leader in the generation
 of genomic intellectual property for the biotechnology and pharmaceutical
 fields.
     The applications filed by Deltagen cover the functional utility of genes
 and additionally claim mammalian models useful for drug screening and
 discovery in a number of key disease areas, including cancer, immune system
 disorders, diabetes, inflammation, neuropsychological disorders, fertility and
 vision.  The applications also cover certain products and technologies,
 including Deltagen's proprietary methods relating to gene targeting, gene
 knockout and transgenic mouse production, and DeltaBase(TM), the company's
 database of gene function information.
     Adding approximately 63 new targets each quarter, DeltaBase currently
 contains 187 potential drug targets, predominantly representing classical drug
 discovery targets such as G-protein-coupled receptors, ion channels and
 proteases.  DeltaBase delivers 250 new gene targets annually, and Deltagen is
 pursuing patent protection on the functional utility of each of these targets.
     "The filing of our 300th application with the USPTO represents a
 significant milestone in Deltagen's rapidly-expanding intellectual property
 portfolio," said William Matthews, Ph. D., president and chief executive
 officer of Deltagen.  "Our USPTO filings, more than  275 in the past year
 alone, reflect Deltagen's continued commitment to drug discovery and
 commercialization efforts in the post-genome era," continued Dr. Matthews.
     Deltagen is a genomic and biotechnology company headquartered in
 Menlo Park, California, that provides data to pharmaceutical and biotechnology
 companies on the function, role and disease relevance of mammalian genes.
 This information may facilitate the discovery and validation of drug targets
 to advance the development of new genomics-based medicines.  Deltagen's
 principal product, DeltaBase(TM) provides a database of in vivo derived,
 mammalian gene function information.  In addition the Company offers a program
 dedicated to determining the function of secreted proteins.  Under this
 program, the Company undertakes the discovery and development of secreted
 protein biotechnology drug candidates internally or in collaboration with
 other parties.  Deltagen's current customers include GlaxoSmithKline plc,
 Merck Inc., Pfizer Inc. and Schering-Plough Research Institute.  The Company's
 current DeltaBase subscribers are GlaxoSmithKline plc and Pfizer Inc.
     NOTE:  This press release contains forward looking statements that are
 subject to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements, including
 uncertainties related to product and drug development, uncertainties related
 to the need for regulatory or other government approvals, the Company's
 patents and other intellectual property, dependence on proprietary technology,
 uncertainty of market acceptance of the company's products, uncertainties
 related to business opportunities, the receipt of future payments, including
 milestones and royalties, the continuation of customer relationships cited in
 the risk factors sections of the Company's Annual Report on Form 10-K filed
 with the Securities and Exchange Commission and the Company's other securities
 filings with the Commission.  These forward-looking statements speak only as
 of the date hereof.  The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 SOURCE  Deltagen, Inc.